Gilead's remdesivir shows modest improvement in moderate COVID-19 patients

Gilead's remdesivir shows modest improvement in moderate COVID-19 patients

Reuters

Published

Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID-19 given a five-day course of the treatment, while those who received the medicine for 10 days in the study did not fare as well.

Full Article